AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution

From lab bench to market: Strengthening translational research in India’s biotech ecosystem

India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

OBESITAS 2026 concludes with focus on India’s rising obesity burden

The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges

JP Nadda highlights India’s push for APIs, biologics and translational research

On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus

Monitra Health raises fresh funding to scale upBeat® cardiac monitoring platform globally

The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans

Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action

Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms